Urocit-K for the Treatment and Prevention of Kidney Stones

You play a major role

The key factor in any medical management program is you . . . the patient. Why? Because it is your unique metabolic pattern, along with the diet you follow (you really are what you eat), that are the major reasons you form stones.

Following your physician's instructions and sticking with the program are the prime elements (along with drinking adequate amounts of water) in reducing your chances of ever having another attack. In other words, it demands a commitment from you, and by you, to adhere to the chosen program on a daily continuing basis for an extended period, possibly for life.

What can be done to avoid recurrence?

Since most kidney stones have calcium in them, for most sufferers there is a specific medical treatment that can greatly reduce the likelihood of your having another stone attack.

Urocit^®-K has been clinically shown to effectively inhibit the formation of most stones in over 90% of patients.

Urocit^®-K is a simple, reliable and cost-effective way of medically managing kidney stones.

Important Safety Information

Contraindications

Patients with hyperkalemia, peptic ulcer disease, active urinary tract infection, and renal insufficiency
Conditions predisposing patients to hyperkalemia, including chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, and extensive tissue breakdown

Warnings and Precautions

Hyperkalemia: In patients with impaired mechanisms for excreting potassium, Urocit-K administration can produce hyperkalemia and cardiac arrest. Potentially fatal hyperkalemia can develop rapidly and be asymptomatic. The use of Urocit-K in patients with chronic renal failure, or any other condition which impairs potassium excretion such as severe myocardial damage or heart failure, should be avoided
Gastrointestinal lesions: If there is severe vomiting, abdominal pain or gastrointestinal bleeding, Urocit-K should be discontinued immediately and the possibility of bowel perforation or obstruction investigated

Patient Counseling Information

Administration of Drug

Patients should be told to take Urocit-K 15 mEq without crushing, chewing, or sucking the tablet
Patients should be told to take Urocit-K 15 mEq only as directed, especially if the patient is also taking both diuretics and digitalis preparations
Patients should be told to check with the doctor if they experience difficulty swallowing the tablet or it seems to stick in the throat
Patients should be told to check with the doctor at once if they notice tarry stools or other signs of gastrointestinal bleeding
Patients should be advised that regular blood tests and electrocardiograms will be performed to ensure safety

Patient Monitoring Information

Hyperkalemia

Patients with impaired mechanisms for excreting potassium should be closely monitored for signs of hyperkalemia with periodic blood tests and ECGs

This material is intended to provide basic information. Patients should discuss all medical advice, diagnosis, and treatment with their healthcare provider.

Please see full Prescribing Information